CD33’s expression on myeloid progenitor cells and leukemia blasts makes it a prime target for antibody-based therapies [140], such as antibody–drug conjugates, that seek to selectively eliminate leukemic cells while sparing normal hematopoietic stem cells. This evidence concerns the gene CD33 and leukemia.